ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO692

Ramipril Therapy in Integrin α1-Null ARAS Mice Triples Lifespan: Mechanistic Clues From RNA-Seq Analysis

Session Information

Category: Glomerular Diseases

  • 1304 Glomerular Diseases: Podocyte Biology


  • Cosgrove, Dominic E., Boystown National Research Hospital, Omaha, Nebraska, United States
  • Madison, Jacob D., Boystown National Research Hospital, Omaha, Nebraska, United States
  • Meehan, Daniel T., Boystown National Research Hospital, Omaha, Nebraska, United States
  • Wilhelm, Kevin O'Connor, Baylor College of Medicine, Houston, Texas, United States
  • Gratton, MichaelAnne, Boystown National Research Hospital, Omaha, Nebraska, United States
  • Samuelson, Gina C., Boystown National Research Hospital, Omaha, Nebraska, United States
  • Fascianella, John A., Boystown National Research Hospital, Omaha, Nebraska, United States

The standard of care for patients with Alport syndrome is ACE inhibitors. In ARAS mice, the ACE inhibitors double lifespan. In humans, ACE inhibitor treatment extends life as well. Any therapy developed must provide significant benefit over ACE inhibition alone. Here we show that integrin α1-null Alport (DKO) mice treated with ramipril live 3X longer than untreated ARAS mice. This effect may be the result of laminin 211-mediated suppression of the transcriptional regulator FOXC2, which reduces expression of nephrin and podocin.


DKO mice were treated with vehicle or ramipril starting at 4 weeks of age. Proteinuria and glomerular filtration rates were measured at 5-week intervals. Glomeruli were analyzed for laminin 211 deposition in the GBM and GBM ultrastructure analyzed by TEM. RNA-seq was performed on isolated glomeruli at various timepoints, and cultured podocytes were overlayed with recombinant laminin 211 or not and RNA analyzed by RNA-seq.


GFR in DKO mice decline between 10 and 15 weeks of age and in ramipril-treated DKO mice at 30 to 35 weeks. Proteinuria followed these same patterns with normalization of GBM architecture in ramipril-treated DKO mice. RNA-seq analysis showed that alteration of gene expression and pathways were similar comparing DKO with ramipril-treated DKO mice with delayed effects in ramipril-treated DKO mice. Decline in expression of nephrin and podocin mRNA and protein occurred but was delayed in the ramipril-treated DKO mice. GBM accumulation of laminin 211 was delayed in ramipril-treated Alport mice, and laminin 211 treatment of podocytes reduced expression of FOXC2 nephrin, and podocin.


Ramipril synergizes with integrin α1 blockade slowing the progression of glomerular disease and tripling the lifespan compared to untreated ARAS mice. The slowed progression involves similar genes and pathways, particularly the transcriptional regulator FOXC2, nephrin, and podocin. Reduced accumulation of laminin 211 in the GBM in treated mice. In vitro, Cultured podocytes exposed to laminin 211 show changes similar to Alport glomeruli.


  • Other NIH Support